Long-Acting Glatiramer Acetate Depot Under Review for Relapsing MS
The FDA has accepted for review the NDA for glatiramer acetate depot 40 mg for the treatment of relapsing forms of multiple sclerosis.
Source: neurologyadvisor.com
📰 Mapi Pharma News
Page 2 - Mapi Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mapi Pharma. Real-time updates on events, politics, business and more.
Cough-assisted Devices Global Market to Register Incremental Growth at a CAGR of ~7% by 2028
/PRNewswire/ -- DelveInsights Cough-assisted Devices Market Insights report provides the current and forecast market analysis, individual leading...
United States Merck Serono Koninklijke Philips Ferrer Internacional Clene Nanomedicine Dima Italia Srl
Source: prnewswire.com
S&P 500 Gains and Losses Today: Stocks Take Off After Earnings Reports
The S&P 500 snapped a four-day losing streak on Monday, Aug. 7, 2023, rising 0.9% after the latest round of earnings reports.
Source: investopedia.com
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
$ Free Cash Flow $2,300 - $2,700 ___________ Includes the full year expected performance for the planned divestitures and excludes any potential related costs, such as taxes and transaction costs,...
Source: marketscreener.com
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris long-standing and...
Source: marketscreener.com
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review - Viatris (NASDAQ:VTRS)
Viatris Inc (NASDAQ: VTRS) reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the 
Source: benzinga.com
Viatris Shares Gain on Sales, Divestitures, and FDA Review of Its MS Drug
Viatris shares advanced after the drugmaker posted better-than-expected results, said it will announce one or more divestitures this quarter, and indicated the FDA agreed to consider approval of its new multiple sclerosis treatment produced with Israel’s Mapi Pharma.
Source: investopedia.com
Markets Higher at Midday on New Earnings Reports, Upcoming Data
U.S. equities were higher at midday on Monday, Aug. 7, 2023, after the latest earnings reports and ahead of key inflation data due later in the week.
Source: investopedia.com
Long-Acting Glatiramer Acetate Depot Under Review for Relapsing MS
The FDA has accepted for review the NDA for glatiramer acetate depot 40mg for the treatment of relapsing forms of multiple sclerosis.
Source: empr.com
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40...
Source: prnewswire.com